title: [Chemotherapy based on EBM in the field of hematological malignancies].
abstract: In the field of hematology/oncology, there are reasonable number of chemotherapy-related reports with level 1 evidences based on the analysis of the evidence based medicine (EBM). Following reasons may be pointed out; the first is that the history of chemotherapy has been initiated in the field of in hematology/oncology so it has more than 50 years' experience. The second is that leukemia and lymphoma are very chemosensitive diseases to compare with solid tumor, so the ultimate goal of their therapy is increase of the cure rate. The third is hematologists with high specialty only can manage such serious patients. Thus they have proposed plenty well-designed and well-organized clinical protocols and have performed some of them in this field. We have learned several recommended therapy of some hematological malignancies with level 1 evidences. It is not so easy, however, to treat all patients according to the best recommended therapy for Japanese patients, because of some limitations of using Japanese health insurance. This is very crucial problem for the patients. We should settle the issue from the scientific and social aspects as soon as possible.
authors.affiliation: Dept. of Hematology, Aichi Cancer Center Hospital, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Ogura
authors.forename: H
authors.initials: H
authors.lastname: Takeuchi
authors.forename: R
authors.initials: R
authors.lastname: Ueda
mesh_terms: D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D009313:National Health Programs; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence